Table 10—

Reduction in 10-year risk of major CVD end points (CHD death/nonfatal MI) in major statin trials, or substudies of major trials, in diabetic subjects (n = 16,032)

Study (ref.)CVD preventionStatin dose and comparatorRRRARRLDL cholesterol reduction
4S-DM (155)20Simvastatin 20–40 mg vs. placebo85.7 to 43.2% (50%)42.5%186 to 119 mg/dl (36%)
ASPEN 20 (160)20Atorvastatin 10 mg vs. placebo39.5 to 24.5% (34%)12.7%112 to 79 mg/dl (29%)
HPS-DM (156)20Simvastatin 40 mg vs. placebo43.8 to 36.3% (17%)7.5%123 to 84 mg/dl (31%)
CARE-DM (157)20Pravastatin 40 mg vs. placebo40.8 to 35.4% (13%)5.4%136 to 99 mg/dl (27%)
TNT-DM (158)20Atorvastatin 80 mg vs. 10 mg26.3 to 21.6% (18%)4.7%99 to 77 mg/dl (22%)
HPS-DM (156)10Simvastatin 40 mg vs. placebo17.5 to 11.5% (34%)6.0%124 to 86 mg/dl (31%)
CARDS (161)10Atorvastatin 10 mg vs. placebo11.5 to 7.5% (35%)4%118 to 71 mg/dl (40%)
ASPEN 10 (160)10Atorvastatin 10 mg vs. placebo11.0 to 7.9% (19%)1.9%114 to 80 mg/dl (30%)
ASCOT-DM (159)10Atorvastatin 10 mg vs. placebo11.1 to 10.2% (8%)0.9%125 to 82 mg/dl (34%)
  • Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and nonfatal MI. In this tabulation, results of the statin on 10-year risk of major CVD end points (CHD death/nonfatal MI) are listed for comparison between studies. Correlation between 10-year CVD risk of the control group and the ARR with statin therapy is highly significant (P = 0.0007). Analyses provided by Craig Williams, Pharm.D., Oregon Health & Science University, 2007. ARR, absolute risk reduction; RRR, relative risk reduction.